A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 21 Mar 2018 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 30 Mar 2016 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2023 as reported by ClinicalTrials.gov.